Summary

Company & vaccine name Versus Wuhan Versus Variants Rates of side effects Severity of side effects Safety & health risks Antibody levels Protection durability Ease of transport Ease of administration
1. Novavax

(Covovax / Nuvaxovid)

1st

(96.4%-100%)

1st

(90%)

1st

(Lowest)

1st

(Lowest)

1st

(Lowest)

1st

(Highest)

1st

(Longest)

1st (tie) 1st (tie)
2. Moderna

(Spikevax)

2nd

(94.1%)

1st 1st 1st 1st 1st 1st last (tie) 2nd to last
3. Pfizer

(Comirnaty)

3rd

(95%)

1st 1st 1st 1st 1st 1st last (tie) last (tie)
4. J & J

(Janssen COVID-19 Vaccine, Ad26.COV2.S)

5th

(58.20%)

1st 1st 1st 1st 1st 1st 1st (tie) 1st (tie)
5. AstraZeneca

(Vaxzevria / Covishield)

4th

(63% - 82%)

1st 1st 1st 1st 1st 1st 1st (tie) 1st (tie)
China comparison:
6. Coronavac Not recommended

(50.40%)

1st 2nd 1st 1st 1st 1st 1st (tie) 1st (tie)
7. Sinopharm low 1st 1st 1st 1st 1st 1st 1st (tie) 1st (tie)

Efficacy Versus Wuhan Strains (lineage B.1)

Vaccine Efficacy Level
1. Novavax 96.4% - 100%
2. Pfizer 95%
3. Moderna 94.1%
4. AstraZeneca 63% - 82%
5. J & J

(versus moderate and severe, would be lower % if mild cases were included)

58.20%
6. Coronavac 50.40%

Efficacy Versus Variants of Interest and Concern

Vaccine Efficacy Level
1. Novavax 90.2%
2. Pfizer 85%
3. Moderna 83.1%
4. AstraZeneca

(versus moderate and severe, would be lower % if mild cases were included)

64%
5. J & J 61%-81%

Efficacy Against Severe Disease and Hospitalization

Vaccine Efficacy Level
1. Novavax 100%
2. Pfizer 100%
3. Moderna 97%
4. AstraZeneca 85%
5. J & J 80%

Mild and Moderate Side Effects

Vaccine Efficacy Level
1. Novavax 100%
2. Pfizer 100%
3. Moderna 97%
4. AstraZeneca

(versus moderate and severe, would be lower % if mild cases were included)

85%
5. J & J 80%

Severe Side Effects

Vaccine Efficacy Level
1. Novavax 100%
2. Pfizer 100%
3. Moderna 97%
4. AstraZeneca

versus moderate and severe, would be lower % if mild cases were included)

85%
5. J & J 80%

Neutralizing Antibody Quantities

Vaccine Efficacy Level
1. Novavax 1400
2. Moderna 1300
3. Pfizer 500
4. J & J 450
5. AstraZeneca

(versus moderate and severe, would be lower % if mild cases were included)

300

Declines in Antibody Quantities

Antibodies have a half-life of about 1 month. This means that each month, the quantity of antibodies drops in half. In other words, by 50%. The lower the quantity drops, the lower the efficacy.

Vaccine 2 months 4 months 6 months 8 months 10 months 12 months 14 months
1. Novavax 1400 35017587.543.821.910.9
2. Moderna 1300 325162.581.340.620.310.2
3. Pfizer 500 12562.531.315.67.83.9
4. J & J 450 112.556.328.114.173.5
5. AstraZeneca

(versus moderate and severe, would be lower % if mild cases were included)

300 7537.518.89.44.72.3

Durability : Drops in Efficacy Overtime

Antibodies have a half-life of about 1 month. This means that each month, the quantity of antibodies drops in half. In other words, by 50%. The lower the quantity drops, the lower the efficacy.

Vaccine 4 months 5 months 6 months 7 months 8 months 9 months 10 months
1. Novavax 650 162.5 81.25 40.62 20.31 10.15 5.07
2. Pfizer
3. Moderna
4. J & J
5. AstraZeneca

Safety / health risks

These are listed from best to worst. The adeno viral vector vaccines (J&J and AstraZeneca) have 4 possible safety problems. But we’ve rated the Pfizer vaccine the worst because it has the highest probability of a safety problem. The 1 in 18,200 rate of myocarditis is higher than all 4 issues of the adeno vaccines combined. The myocarditis rate of the Moderna vaccine appears to be lower, but it’s based on a lower quantity of patients. Thus it could turn out that Moderna’s rate is almost as high as Pfizer’s. At the same time, the 4 safety problems of the adeno vaccines are on average more harmful than the RNA safety issue.

Vaccine Myocarditis

(Heart inflammation)

TTS

(Blood clots)

Anaphylaxis

(Severe allergy)

Guillain-Barré Syndrome CVST

(Blood clots)

1. Novavax No No No No No
2. Pfizer Yes - 1 per 77,000

(1,300 per 100m)

No No No No
3. Moderna 1 in 300,000 Yes Yes Possible Yes - 1 per 285k
4. J & J No Yes - 1 per 100,000 Yes - 1 per 79,100

(1,300 per 100m)

Possible

(1,200 per 100m)

Yes - 1 per 285k

(138 per 100m)

5. AstraZeneca Yes - 1 per 18,200
Odds of a commercial airplane crashing: 1 in 3 million (33 per 100m)
Odds of dying on a commercial flight: 1 in 12.5 million (8 per 100m)

Ease of Transport and Administration

Vaccine Transport temperature Storage temperature Hours OK at room temperature
1. Novavax 2 to 8 degrees Celsius

(45 to 60 Fahrenheit)

2. Pfizer
3. Moderna
4. J & J
5. AstraZeneca